Intraocular Inflammation
VIDEO: OTX-TKI for NPDR shows promising safety, tolerability at 48 weeks
In this Healio Video Perspective from the ASRS meeting, Dilsher Dhoot, MD, of California Retina Consultants discusses interim safety and efficacy results for OTX-TKI for the treatment of nonproliferative diabetic retinopathy.
Real-world study explores safety of pegcetacoplan in geographic atrophy
The first analysis of real-world outcomes in patients with neovascular age-related macular degeneration treated with pegcetacoplan for geographic atrophy demonstrated similar safety seen in clinical trials, according to a study.
Dexamethasone intracanalicular insert may be effective for aqueous-deficient dry eye
A dexamethasone 0.4 mg intracanalicular insert was linked to greater improvement in corneal and conjunctival staining vs. a sham collagen plug among patients with aqueous-deficient dry eye, although it may increase IOP, research showed.
BLOG: Optometrists, retina specialists, industry work together to slow progression of GA
Age-related macular degeneration is the leading cause of vison loss among older adults.
Lumevoq shows sustained efficacy, safety 4 years after one-time LHON treatment
Lumevoq demonstrated sustained efficacy and a positive safety profile at 4 years after a one-time injection of the gene therapy in patients with Leber hereditary optic neuropathy, according to a press release from GenSight Biologics.
Early safety, efficacy results positive for Restoret in DME, wet AMD
Restoret showed promising safety and efficacy results at 12 weeks in patients with treatment-naive diabetic macular edema and treatment-naive neovascular age-related macular degeneration, according to a press release from EyeBio.
VIDEO: Lessons can be learned from terminated galegenimab study
SEATTLE — In this Healio Video Perspective from the ASRS meeting, David A. Eichenbaum, MD, FASRS, overviews the efficacy of aHtrA1 Fab for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
ASRS ReST Committee sheds light on timeline of Syfovre inflammation reports
SEATTLE — At the American Society of Retina Specialists annual meeting, the ReST Committee shared an update on intraocular inflammation reported in patients who received Syfovre.
BLOG: What’s next for Beovu?
On the heels of the major announcement from Novartis that Beovu should not be used in intervals less than 8 weeks, some are wondering what the ultimate future of the drug will be.
Man presents with unilateral decreased vision
A 30-year-old man presented to the New England Eye Center for decreased vision with a central black spot in his vision for 1 week. He denied flashes, floaters, pain and headache.